Recombinant rotavirus inner core proteins produced in the milk of transgenic rabbits confer a high level of protection after intrarectal delivery

Vaccine

Volumn 25, Issue 34, 2007, Pages 6373-6380

  Soler, Eric ^a   Parez, Nathalie ^b   Passet, Bruno ^c   Dubuquoy, Catherine ^d   Riffault, Sabine ^d   Pillot, Matthieu ^c   Houdebine, Louis Marie ^a   Schwartz Cornil, Isabelle ^d  

^a INRA Institut National de la Recherche Agronomique   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c CEMAGREF   (France)

^d INRA Institut National de la Recherche Agronomique   (France)

Author keywords

Mucosal; Rotavirus; Transgenic

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PROTEIN VP2; PROTEIN VP6; ROTAVIRUS VACCINE; SECRETORY IMMUNOGLOBULIN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; ROTAVIRUS; TH1 CELL; TRANSGENIC ANIMAL; VIRAL GASTROENTERITIS; VIRUS LIKE AGENT; VIRUS SHEDDING;

EID: 34547132569     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.011     Document Type: Article

References (47)

1. Parashar U.D., Gibson C.J., Bresse J.S., and Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 2 (2006) 304-306
2. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., and Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9 5 (2003) 565-572
3. Bresee J.S., Glass R.I., Ivanoff B., and Gentsch J.R. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 17 18 (1999) 2207-2222
4. Kosek M., Bern C., and Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 81 3 (2003) 197-204
5. Glass R.I., Parashar U.D., Bresee J.S., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 368 9532 (2006) 323-332
6. Glass R.I., and Parashar U.D. The promise of new rotavirus vaccines. N Engl J Med 354 1 (2006) 75-77
7. Parashar U.D., and Glass R.I. Public health. Progress toward rotavirus vaccines. Science 312 5775 (2006) 851-852
8. Kapikian A.Z., Hoshino Y., Chanock R.M., and Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 174 Suppl. 1 (1996) S65-S72
9. CDC. Centers for Disease Control and Prevention: withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 48 43 (1999) 1007
10. Clark H.F., Offit P.A., Ellis R.W., et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 174 Suppl. 1 (1996) S73-S80
11. Bernstein D.I., Sack D.A., Rothstein E., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 354 9175 (1999) 287-290
12. Desselberger U. RotaTeq (Sanofi Pasteur/Wistar Institute/Children's Hospital of Philadelphia). Curr Opin Investig Drugs 6 2 (2005) 199-208
13. Vesikari T., Karvonen A., Korhonen T., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 22 21-22 (2004) 2836-2842
14. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 1 (2006) 11-22
15. Vesikari T., Clark H.F., Offit P.A., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24 22 (2006) 4821-4829
16. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., and Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21 25-26 (2003) 3885-3900
17. Choi A.H., Basu M., McNeal M.M., et al. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol 74 24 (2000) 11574-11580
18. O'Neal C.M., Crawford S.E., Estes M.K., and Conner M.E. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71 11 (1997) 8707-8717
19. Wigdorovitz A., Mozgovoj M., Santos M.J., et al. Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants. J Gen Virol 85 Pt 7 (2004) 1825-1832
20. Wu Y.Z., Li J.T., Mou Z.R., et al. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology 313 2 (2003) 337-342
21. Yu J., and Langridge W. Expression of rotavirus capsid protein VP6 in transgenic potato and its oral immunogenicity in mice. Transgenic Res 12 2 (2003) 163-169
22. Soler E., Le Saux A., Guinut F., et al. Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits. Transgenic Res 14 (2005) 833-844
23. Ciarlet M., Crawford S.E., Barone C., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 72 11 (1998) 9233-9246
24. Parez N., Fourgeux C., Mohamed A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80 4 (2006) 1752-1761
25. Agnello D., Herve C.A., Lavaux A., et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 80 8 (2006) 3823-3832
26. Houdebine L.M. Use of transgenic animals to improve human health and animal production. Reprod Domest Anim 40 4 (2005) 269-281
27. Echelard Y. Recombinant protein production in transgenic animals. Curr Opin Biotechnol 7 5 (1996) 536-540
28. Houdebine L.M. Transgenic animal bioreactors. Transgenic Res 9 4-5 (2000) 305-320
29. DRD. Recombinant human antithrombin III: rhATIII. Drugs R D 5 2 (2004) 110-112
30. Yeung P.K. Transgenic antithrombin III (Genzyme). IDrugs 3 6 (2000) 669-673
31. Schwartz-Cornil I., Benureau Y., Greenberg H., Hendrickson B.A., and Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 76 16 (2002) 8110-8117
32. Tudor D., Riffault S., Carrat C., Lefevre F., Bernoin M., and Charley B. Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C. Virology 286 1 (2001) 197-205
33. Soler, E., Fourgeux, C., Parez, N. et al. Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals. In: European Patent Reference (EPO), 2004.
34. Choi A.H., McNeal M.M., Basu M., et al. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20 27-28 (2002) 3310-3321
35. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 19-20 (2002) 2431-2438
36. Hervas-Stubbs S., Rueda P., Lopez L., and Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I interferon. J Immunol 178 (2007) 2361-2869
37. McNeal M.M., Stone S.C., Basu M., et al. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology 346 2 (2006) 338-347
38. Choi A.H., Basu M., McNeal M.M., Bean J.A., Clements J.D., and Ward R.L. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice. Protein Exp Purif 38 2 (2004) 205-216
39. Burns J.W., Siadat-Pajouh M., Krishnaney A.A., and Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272 5258 (1996) 104-107
40. Thouvenin E., Schoehn G., Rey F., et al. Antibody inhibition of the transcriptase activity of the rotavirus DLP: a structural view. J Mol Biol 307 1 (2001) 161-172
41. Corthesy B., Benureau Y., Perrier C., et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80 21 (2006) 10692-10699
42. VanCott J.L., Prada A.E., McNeal M.M., et al. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates. J Virol 80 10 (2006) 4949-4961
43. McNeal M.M., VanCott J.L., Choi A.H., et al. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol 76 2 (2002) 560-568
44. Smiley K.L., McNeal M.M., Basu M., Choi A.H., Clements J.D., and Ward R.L. Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J Virol 81 8 (2007) 3740-3748
45. Fromantin C., Jamot B., Cohen J., Piroth L., Pothier P., and Kohli E. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response. J Virol 75 22 (2001) 11010-11016
46. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 2 (2006) 148-158
47. Eriksson K., Quiding-Jarbrink M., Osek J., et al. Anatomic segmentation of the intestinal immune response in nonhuman primates: differential distribution of B cells after oral and rectal immunizations to sites defined by their source of vascularization. Infect Immun 67 11 (1999) 6210-6212